Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Kythera Faces Advisory Committee Meeting For Double Chin Drug

The California biotech faces one last hurdle before potential approval of its double chin injectable ATX-101 when it comes in front of the FDA’s dermatology advisory committee.

Deals Of The Week Looks At 2014 Takeout Targets

The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.

Kythera Doubles Down On Double Chins With Bayer Buyback

The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS052577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel